icon- folder.gif   Conference Reports for NATAP  
 
  20th Conference on Retroviruses and
Opportunistic Infections
Atlanta, GA March 3 - 6, 2013
 Back grey_arrow_rt.gif
 
 
 
HCV at CROI
 
 
  · CROI: Hepatic Fibrosis and Immune Phenotypes Vary by Hepatitis C Viremia in HIV Infection: A Women's Interagency HIV Study.....[from Jules: HCV Viremia Increased Fibrosis/Immune-Dysregulation; HIV Drives Immune Activation but HCV Contributes to Immune Activation] - (03/15/13)
 
· CROI: The Effect of Hepatic Fibrosis and HCV viremia on Serum Inflammatory Mediators in HIV Infection - a Women's Interagency HIV Study - (03/15/13)
 
· CROI: Treatment of Acute HCV in HIV-infected MSM Incorporating Telaprevir - (03/13/13)
 
· CROI: Telaprevir Combination Treatment in Hard-to-treat African American, Null Responder G1 Chronic Hepatitis C Patients: Early Data From the OUTLOOK Study - (03/09/13)
 
· CROI: Telaprevir, Peginterferon and Ribavirin Combination Therapy for Chronic HCV Genotype 1 in HCV/HIV Co-infected Patients: Early Response and Viral Resistance - (03/09/13)
 
· CROI: High Early Virological Response with Telaprevir-PegIFN-RBV in treatment-experienced, HCV genotype 1, HIV coinfected patients: ANRS HC26 TelapreVIH Study - (03/08/13)
 
· CROI: ANRS-HC27 BocepreVIH Interim Analysis: High EVR with Boceprevir+peg-IFN+ RBV in HCV/HIV-co-infected Patients with Previous Failure to peg-IFN+RBV - (03/08/13)
 
· CROI: Simeprevir (TMC435) with peginterferon/ribavirin in patients co-infected with chronic genotype-1 HCV and HIV-1: Week-24 interim analysis of the TMC435-C212 study - (03/07/13)
 
· CROI: High Efficacy of Sofosbuvir in Combination with Weight Based Ribavirin for 24 weeks in Difficult to Treat HCV Infected Genotype-1 Patients - (03/06/13)
 
· CROI: COSMOS Study SVR4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 null responders - (03/06/13)
 
· Regulatory Application has now been filed for Simeprevir (TMC435) in Japan for the treatment of genotype 1 hepatitis C patients - (03/05/13)
 
· CROI: First interim results from a phase IIa study evaluating an all-oral regimen of Simeprevir and Sofosbuvir in prior null responder Hepatitis C patients - press release - (03/04/13)
 
· CROI: ELECTRON: 100% SVR Rate for Once-Daily Sofosbuvir Plus Ledipasvir Plus Ribavirin Given for 12 Weeks in Treatment-Naïve and Previously Treated Patients With HCV GT 1 - (03/04/13)
 
· CROI: RISK OF VIROLOGIC RELAPSE IN HEPATITIS C, GENOTYPE 1-INFECTED SUBJECTS AFTER 8, 12, OR 24 WEEKS OF TREATMENT WITH ABT-450/r + ABT-267 + ABT-333 + RBV: IDENTIFYING OPTIMAL TREATMENT DURATION - (03/04/13)
 
· CROI: 12 WEEKS OF ABT-450/r, NON-NUCLEOSIDE INHIBITOR AND RBV ACHIEVED SVR24 IN >90% OF TREATMENT-NAïVE HCV GT1 PATIENTS AND 47% OF PRIOR NONRESPONDERS - (03/04/13)
 
· CROI: Pharmacokinetic interactions of darunavir/ritonavir, efavirenz, and tenofovir with the HCV protease inhibitor faldaprevir in healthy volunteers - (03/04/13)
 
· CROI: STARTVerso 4: High rates of early virologic response in HCV genotype 1/HIV-co-infected patients treated with faldaprevir plus pegIFN and RBV - (03/04/13)
 
· CROI: Boerhinger Ingelheim Announes Interim Results Evaluating Virologic Response Rates in HCV/HIV Coinfected Patients Treated with HCV Protease BI201335, and Drug Drug Interaction Studies with HIV ARTs - (03/04/13)